{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:45:01Z","timestamp":1787791501608,"version":"build-2784847793"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":73,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100354","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T21:01:09Z","timestamp":1616101269000},"page":"100354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review"],"prefix":"10.1016","volume":"27","author":[{"given":"Alessandro","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100354_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820948047","article-title":"Immunotherapy in biliary tract cancer: worthy of a second look","volume":"27","author":"Ricci","year":"2020","journal-title":"Cancer Control"},{"issue":"9","key":"10.1016\/j.ctarc.2021.100354_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0004","first-page":"1","article-title":"Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer","author":"Rizzo","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100354_bib0005","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100354_bib0006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0007","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2021.100354_bib0008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int."},{"issue":"8","key":"10.1016\/j.ctarc.2021.100354_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New treatment options for advanced biliary tract cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr. Treat. Opt. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100354_bib0010","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","article-title":"Systemic therapies for intrahepatic cholangiocarcinoma","volume":"72","author":"Kelley","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0011","first-page":"10","article-title":"New horizons for precision medicine in biliary tract cancers","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2021.100354_bib0012","first-page":"1","article-title":"Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer","author":"Rizzo","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol"},{"key":"10.1016\/j.ctarc.2021.100354_bib0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.14701\/ahbps.2020.24.1.6","article-title":"The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: review of literature and pooled analysis","volume":"24","author":"Kamarajah","year":"2020","journal-title":"Ann. Hepatobil. Pancreat Surg."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100354_bib0014","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.ctarc.2021.100354_bib0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.21873\/cgp.20203","article-title":"Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives","volume":"17","author":"Rizzo","year":"2020","journal-title":"Cancer Genomic. Proteomic."},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0017","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100354_bib0018","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100354_bib0019","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/jgo.2017.05.04","article-title":"Current biologics for treatment of biliary tract cancer","volume":"8","author":"Zhao","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0020","first-page":"1","article-title":"Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives","author":"Rizzo","year":"2020","journal-title":"Expert. Opin. Invest. Drugs"},{"issue":"8","key":"10.1016\/j.ctarc.2021.100354_bib0021","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers12082308","article-title":"Evolution of the experimental models of cholangiocarcinoma","volume":"12","author":"Massa","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100354_bib0022","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-016-0432-2","article-title":"Genomic profiling of biliary tract cancers and implications for clinical practice","volume":"17","author":"Jain","year":"2016","journal-title":"Curr. Treat. Opt. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2021.100354_bib0023","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2021.100354_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001042","article-title":"The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?","volume":"5","author":"Ricci","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2021.100354_bib0025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ctrv.2018.09.002","article-title":"Biliary tract cancer: state of the art and potential role of DNA damage repair","volume":"70","author":"Lamarca","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100354_bib0026","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bpg.2015.02.001","article-title":"Clinical presentation, risk factors and staging systems of cholangiocarcinoma","volume":"29","author":"Plentz","year":"2015","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"16","key":"10.1016\/j.ctarc.2021.100354_bib0027","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2021.100354_bib0028","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctarc.2021.100354_bib0029","first-page":"1","article-title":"BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care","author":"Rizzo","year":"2020","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctarc.2021.100354_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctarc.2021.100354_bib0032","first-page":"1","article-title":"Recent advances of immunotherapy for biliary tract cancer","author":"Rizzo","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol"},{"key":"10.1016\/j.ctarc.2021.100354_bib0033","article-title":"Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: a systematic review","author":"Fruscione","year":"2020","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ctarc.2021.100354_bib0034","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","article-title":"Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis","volume":"45","author":"Yadav","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2021.100354_bib0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.suc.2013.12.004","article-title":"Distal cholangiocarcinoma","volume":"94","author":"Dickson","year":"2014","journal-title":"Surg. Clin. North Am"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100354_bib0036","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.soc.2019.06.014","article-title":"Approaches and outcomes to distal cholangiocarcinoma","volume":"28","author":"Lee","year":"2019","journal-title":"Surg. Oncol. Clin. N Am."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100354_bib0037","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5604\/16652681.1226927","article-title":"Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes","volume":"16","author":"Waseem","year":"2017","journal-title":"Ann. Hepatol"},{"key":"10.1016\/j.ctarc.2021.100354_bib0038","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9610(97)00203-1","article-title":"Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma","volume":"174","author":"McMasters","year":"1997","journal-title":"Am. J. Surg."},{"issue":"1","key":"10.1016\/j.ctarc.2021.100354_bib0039","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijrobp.2008.07.008","article-title":"Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma","volume":"73","author":"Nelson","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"18","key":"10.1016\/j.ctarc.2021.100354_bib0040","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.3748\/wjg.v23.i18.3301","article-title":"Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma","volume":"23","author":"Jung","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.3_suppl.402","article-title":"Neoadjuvant chemoradiation therapy for cholangiocarcinoma to improve R0 resection rate: the first report of phase II study","volume":"33","author":"Katayose","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100354_bib0042","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1007\/s00268-018-4558-1","article-title":"Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma","volume":"42","author":"Sumiyoshi","year":"2018","journal-title":"World J. Surg"},{"key":"10.1016\/j.ctarc.2021.100354_bib0043","article-title":"Outcomes of neoadjuvant therapy for cholangiocarcinoma: a review of existing evidence assessing treatment response and R0 resection rate","author":"Le","year":"2020","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0044","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/cncr.11401","article-title":"Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study","volume":"97","author":"Wiedmann","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100354_bib0045","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0168-8278(00)80083-5","article-title":"Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma","volume":"32","author":"Berr","year":"2000","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.ctarc.2021.100354_bib0046","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/hpb.12150","article-title":"Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review","volume":"16","author":"Grendar","year":"2014","journal-title":"HPB (Oxford)"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100354_bib0047","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.cgh.2017.04.044","article-title":"Validation of the mayo clinic staging system in determining prognoses of patients with perihilar cholangiocarcinoma","volume":"15","author":"Coelen","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0048","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11912-020-00910-1","article-title":"Liver transplantation for cholangiocarcinoma: insights into the prognosis and the evolving indications","volume":"22","author":"Panayotova","year":"2020","journal-title":"Curr. Oncol. Rep"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100354_bib0049","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/lt.24955","article-title":"Current status of liver transplantation for cholangiocarcinoma","volume":"24","author":"Goldaracena","year":"2018","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100354_bib0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1432-2277.2010.01108.x","article-title":"Liver transplantation for cholangiocarcinoma","volume":"23","author":"Rosen","year":"2010","journal-title":"Transpl. Int"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100354_bib0051","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100354_bib0052","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hpb.12082","article-title":"Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience","volume":"16","author":"Duignan","year":"2014","journal-title":"HPB (Oxford)"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100354_bib0053","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/TP.0000000000003114","article-title":"Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: the irish experience of the mayo protocol","volume":"104","author":"Zaborowski","year":"2020","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100354_bib0054","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.gtc.2018.01.002","article-title":"Liver transplant for cholangiocarcinoma","volume":"47","author":"Zamora-Valdes","year":"2018","journal-title":"Gastroenterol. Clin. North Am"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100354_bib0055","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.21107","article-title":"Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma","volume":"13","author":"Mantel","year":"2007","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0056","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17474124.2017.1309290","article-title":"Intrahepatic cholangiocarcinoma: current management and emerging therapies","volume":"11","author":"Rahnemai-Azar","year":"2017","journal-title":"Expert. Rev. Gastroenterol. Hepatol"},{"key":"10.1016\/j.ctarc.2021.100354_bib0057","article-title":"Outcomes of neoadjuvant therapy for cholangiocarcinoma: a review of existing evidence assessing treatment response and R0 resection rate","author":"Le","year":"2020","journal-title":"J. Surg. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2021.100354_bib0058","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","article-title":"Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches","volume":"155","author":"Tsilimigras","year":"2020","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100354_bib0059","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1245\/s10434-012-2312-8","article-title":"Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study","volume":"20","author":"Kato","year":"2013","journal-title":"Ann. Surg. Oncol"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100354_bib0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"Br. J. Surg"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0061","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/lt.25052","article-title":"Liver transplantation for intrahepatic cholangiocarcinoma","volume":"24","author":"Lee","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ctarc.2021.100354_bib0062","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amsu.2020.07.028","article-title":"Living donor liver transplantation for intra hepatic cholangiocarcinoma","volume":"57","author":"Hafeez Bhatti","year":"2020","journal-title":"Ann. Med. Surg. (Lond.)"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100354_bib0063","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Methodist\u2013MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2021.100354_bib0064","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-020-0314-8","article-title":"Modern therapeutic approaches for the treatment of malignant liver tumours","author":"Petrowsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"11","key":"10.1016\/j.ctarc.2021.100354_bib0065","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.ctarc.2021.100354_bib0066","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.RVI.0000143768.60751.78","article-title":"Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution","volume":"16","author":"Burger","year":"2005","journal-title":"J. Vasc. Interv. Radiol."},{"issue":"6","key":"10.1016\/j.ctarc.2021.100354_bib0067","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00270-007-9032-7","article-title":"Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma","volume":"30","author":"Herber","year":"2007","journal-title":"Cardiovasc. Intervent. Radiol"},{"key":"10.1016\/j.ctarc.2021.100354_bib0068","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ijc.26407","article-title":"Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success","volume":"131","author":"Vogl","year":"2012","journal-title":"Int. J. Cancer"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:02Z","timestamp":1762842002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":68,"alternative-id":["S2468294221000526"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100354","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100354"}}